Search

Search Constraints

You searched for: Author/Creator Gordon, Leo I.

Search Results

1. A phase I/II trial of bortezomib combined concurrently with gemcitabine for relapsed or refractory DLBCL and peripheral T‐cell lymphomas. (8th August 2013)

2. A phase I/II trial of brentuximab vedotin plus rituximab as frontline therapy for patients with immunosuppression-associated CD30+ and/or EBV + lymphomas. Issue 14 (6th December 2021)

4. Comparison of referring and final pathology for patients with T‐cell lymphoma in the National Comprehensive Cancer Network. Issue 13 (4th April 2014)

5. Comparison of referring and final pathology for patients with T‐cell lymphoma in the National Comprehensive Cancer Network. Issue 13 (4th April 2014)

6. De novo emergence of SARS‐CoV‐2 spike mutations in immunosuppressed patients. Issue 6 (1st August 2022)

7. Evaluation of the International Prognostic Score (IPS‐7) and a Simpler Prognostic Score (IPS‐3) for advanced Hodgkin lymphoma in the modern era. (7th September 2015)

8. Frontline bortezomib and rituximab for the treatment of newly diagnosed high tumour burden indolent non‐Hodgkin lymphoma: a multicentre phase II study. (25th April 2014)

10. F‐18 FDG‐PET predicts outcomes for patients receiving total lymphoid irradiation and autologous blood stem‐cell transplantation for relapsed and refractory Hodgkin lymphoma. (15th March 2014)